GSK seeks approval for Breo in asthma; Pfizer under fire for event spending;

> GlaxoSmithKline ($GSK) and partner Theravance ($THRX) have U.S. approval to market Breo Ellipta for patients with asthma. Report

> AstraZeneca ($AZN) has filed a lawsuit against Mylan ($MYL) in the U.S. to block a generic version of diabetes drug Onglyza. More

> Bayer has named three employees to new U.S. government relations and external communications roles. Release

> Argentina has approved Sanofi's ($SNY) Lemtrada to treat for multiple sclerosis. Release

> Astellas has appointed Tatjana Dragovic as its VP and regional compliance officer for its Americas region. Report 

> ANI Pharmaceuticals has acquired Lithobid Extended Release tablets from Noven Therapeutics. Release

> The FDA has updated the label of NPS Pharmaceuticals' sole product, Gattex. More

And Finally... Pfizer ($PFE) has agreed to pay a $5,000 fine for failing to report spending on a reception it hosted during the 2012 Democratic National Convention. Story


Suggested Articles

Amgen could soon face new competition in the PCSK9 class, but an efficacy boost in treating high-risk heart attack patients could help keep it ahead.

Having already whiffed on one crucial heart failure trial, Novartis is focusing on "profound" data from its Entresto studies in hopes for another go.

Bristol-Myers Squibb and Pfizer's Eliqus has taken the U.S. warfarin alternative market by storm, but can AFib screening amp it up even more?